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Neuropathic pain refers to pain due to injury or diseases of the peripheral or central
nervous system.1-3 It is associated with severe, chronic sensory disturbances
characterized by spontaneous pain, increased responsiveness to painful stimuli
(hyperalgesia), and pain perceived in response to normally innocuous stimuli
(allodynia).4,5 Prevalent symptoms in human patients include cold hyperalgesia,
mechanical allodynia, and, less commonly, heat hyperalgesia. Chronic neuro-
pathic pain remains a significant clinical problem and is often resistant to conven-
tional analgesics, therefore, multimodal therapeutic options have been proposed.1-3
Guanylyl cyclase catalyzes the formation of cyclic guanosine monophosphate
(cGMP) from GTP, leading to the synthesis of cGMP, whereas cGMP-specific
phosphodiesterase catalyzes the hydrolysis of cGMP to GMP.2 Accordingly, intra-
cellular cGMP concentrations are regulated by the action of guanylyl cyclase and
the rate of degradation by cGMP-specific phosphodiesterase.6,7
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Purpose: The inhibition of phosphodiesterase 5 produces an antinociception through the increase of cyclic
guanosine monophosphate (cGMP), and increasing cGMP levels enhance the release of γ-aminobutyric acid
(GABA). Furthermore, this phosphodiesterase 5 plays a pivotal role in the regulation of the vasodilatation
associated to cGMP. In this work, we examined the contribution of GABA receptors to the effect of sildenafil, a
phosphodiesterase 5 inhibitor, in a neuropathic pain rat, and assessed the hemodynamic effect of sildenafil in
normal rats. Materials and Methods: Neuropathic pain was induced by ligation of L5/6 spinal nerves in Sprague-
Dawley male rats. After observing the effect of intravenous sildenafil on neuropathic pain, GABAA receptor
antagonist (bicuculline) and GABAB receptor antagonist (saclofen) were administered prior to delivery of sildenafil
to determine the role of GABA receptors in the activity of sildenafil. For hemodynamic measurements, catheters
were inserted into the tail artery. Mean arterial pressure (MAP) and heart rate (HR) were measured over 60 min
following administration of sildenafil. Results: Intravenous sildenafil dose-dependently increased the withdrawal
threshold to the von Frey filament application in the ligated paw. Intravenous bicuculline and saclofen reversed the
antinociception of sildenafil. Intravenous sildenafil increased the magnitude of MAP reduction at the maximal
dosage, but it did not affect HR response. Conclusion: These results suggest that sildenafil is active in causing
neuropathic pain. Both GABAA and GABAB receptors are involved in the antinociceptive effect of sildenafil.
Additionally, intravenous sildenafil reduces MAP without affecting HR.
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INTRODUCTION
It has been suggested that cGMP is involved in antinoci-
ception.8 In line with this observation, dibutyryl-cGMP and
8-bromo-cGMP showed antinociception in a modification
of the Randall-Selitto hyperalgesia model and in a neuro-
pathic pain model, respectively.7,9 Furthermore, sildenafil, a
phosphodiesterase 5 inhibitor, caused antinociception in
carrageenan-induced hyperalgesia, the writhing test and
the formalin test.10-14 In a previous study, increasing cGMP
levels with the phosphodiesterase inhibitor zaprinast enha-
nced the γ-aminobutyric acid (GABA) release.15 Recently,
the antinociception of sildenafil was shown to be reversed
by a GABAB receptor antagonist in the formalin test.16
These observations suggest that GABA receptors may be
involved in the activity of sildenafil. 
On the other hand, the activity of phosphodiesterase 5
was detected in smooth muscle cells of vessels.17 Also,
cGMP plays important role in the regulation of vascular
tone,18 and it has recently been reported that phosphodies-
terase 5 is the key enzyme involved in the regulation of the
cGMP-associated vascular relaxation.19 Therefore, hemo-
dynamic change due to vasodilating effect of phosphodie-
sterase 5 inhibitor is expected. 
In this study, we examined the effect of intravenous
sildenafil in a rat neuropathic pain model and attempted to
clarify the role of GABA receptors in the action of sildenafil.
Furthermore, we observed the change of hemodynamics
following administration of intravenous sildenafil in heal-
thy rats.
Animal preparation
This study proposal was reviewed and approved by the
Institutional Animal Care Committee, Research Institute of
Medical Science, Chonnam National University. Sprague-
Dawley male rats, weighing 100-200 g, were used in all
experiments. Animals were acclimated to the laboratory
environment for 5-7 days before being used in the study.
While in the home cage environment, the animals were
allowed free access to a standard rat diet and tap water.
Room temperature was maintained at 20-23˚C with 12 : 12
h light/dark cycle.
Neuropathic pain model
Neuropathic pain was evoked by spinal nerve ligation of
experimental rats as previously described.20 Briefly, the left
L5 and L6 spinal nerves of rats were isolated adjacent to the
vertebral column during isoflurane anesthesia and tightly
ligated with a 6-0 silk suture distal to the dorsal root ganglia.
Care was taken to avoid injury of the L4 spinal nerve.
Following surgery, development of neuropathic pain was
evaluated daily by measuring the mechanical sensitivity of
the injured paw. Animals were considered to be in neuro-
pathic pain when they exhibited mechanical allodynia i.e.,
paw flinching behavior response to the application of a
bending force of less than 4 g. All animals were allowed to
recover for at least 1 week. 
Assessment of mechanical allodynia
Mechanical allodynia was measured using calibrated von
Frey filaments as previously described.21 Rats were placed
into inverted individual plastic containers (20×12.5×20
cm) on top of a suspended wire mesh grid, and acclimated
to the test chambers for 20 min. A series of eight von Frey
filaments (0.4, 0.7, 1.2, 2.0, 3.6, 5.5, 8.5, and 15 g) were
applied vertically to the plantar surface of the hindpaw for
5 s while the hair was bent. Brisk withdrawal or paw
flinching was considered positive responses. In the absence
of a response at a pressure of 15 g, animals were assigned
to this cut-off value. Tests were performed in duplicate
with an approximate 3 min test-free period between with-
drawal responses, and their average was used. Positive res-
ponses included an abrupt withdrawal of the hind paw from
the stimulus, or flinching behavior immediately following
removal of the stimulus. 
Drugs and administration
The following drugs were used in this study: sildenafil
(phosphodiesterase 5 inhibitor), bicuculline (GABAA
receptor antagonist, Sigma Aldrich Co., St. Louis, MO,
USA) and saclofen (GABAB receptor antagonist, Sigma).
Sildenafil was kindly provided by Korea Pfizer. All drugs
were dissolved in normal saline. For the intravenous admi-
nistration of these agents, the tail vein was used. For intra-
venous administration, drugs and saline were injected in
volumes of 3 mL/kg.
Hemodynamic measurement
In order to measure hemodynamic changes, a polyethy-
lene-50 catheter was inserted into the tail artery under
isoflurane (3-4%)/O2 anesthesia, and the rats were then
restrained in a restraint cylinder. The catheter was flushed
with 0.5 mL of heparinized saline. The arterial line was
connected to a pressure transducer of monitor (Datex-
Ohmeda AS/3, GE Healthcare, Helsinki, Finland) for
continuous recording of blood pressure and heart rate.
Experimental paradigm
Seven days after nerve ligation, sildenafil was administered
intravenously and mechanical threshold for paw flinching
was measured at 15, 30, 45, 60, 90, 120, 150, and 180 min
after delivery of sildenafil. Measurement of the mechanical
threshold for paw flinching was also carried out before
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MATERIALS AND METHODS
surgery (preoperative control). The control study was per-
formed using intravenous saline. The investigator was
blind to the drug given to the experimental animals.
Effect of intravenous sildenafil on neuropathic pain 
and hemodynamics
To examine its effect, saline and sildenafil (1, 3, 10, and 30
mg/kg, n = 37) were intravenously administered, and the
mechanical threshold was measured with the above-
mentioned method. Additionally, blood pressure and heart
rate were measured in normal rats following intravenous
administration of saline and sildenafil (1, 3, 10, and 30
mg/kg, n = 25).
Role of GABA receptors in the action of sildenafil
To investigate the role of GABA receptors in the action of
sildenafil, GABAergic antagonists were intravenously
administered 10 min prior to the delivery of intravenous
sildenafil, and changes of the effect of sildenafil were exam-
ined after pretreatment with GABAA receptor antagonist
(bicuculline, 16 mg/kg, n = 7) or GABAB receptor antago-
nist (saclofen, 16 mg/kg, n = 8). The maximum doses of
bicuculline and saclofen used were chosen based on pre-
vious experiments22 and the pilot study was performed to
examine whether the maximum dosages of bicuculline (n
= 5) and saclofen (n = 6) affected the paw withdrawal thre-
shold or not.
Statistical analysis
Data are expressed as mean ± SEM. The time response
data are presented as paw withdrawal threshold to mecha-
nical stimulation or percentage change from the baseline
mean arterial blood pressure (MAP) and heart rate (HR).
The dose-response data are presented as percentage of
maximal possible effect (%MPE) according to the formula.23
%MPE =
Postdrug threshold - baseline threshold    
×100
Cut-off threshold (15) - baseline threshold
The dose-response data were analyzed using one-way
analysis of variance with Scheffe post hoc analysis. Com-
parison of antagonism for the effect of sildenafil was
analyzed by unpaired t-test. The baseline MAP and HR of
the several groups were examined by one-way analysis of
variance. The effect of sildenafil on MAP and HR was
examined by repeated-measures analysis of variance.
Values of p < 0.05 were considered statistically significant.
Antinociceptive effect of intravenous sildenafil
In control groups, a paw withdrawal threshold was 11-12
g. After nerve ligation, a paw withdrawal threshold was
significantly decreased in a pathologic site. As shown in
Fig. 1A and B, intravenous sildenafil resulted in a dose-
dependent increase of the paw withdrawal threshold (p <
0.05, p < 0.01).
GABA receptors on the activity of sildenafil
Intravenous GABAA antagonist (bicuculline, p < 0.01)
and GABAB antagonist (saclofen, p < 0.05) reversed the
antinociception of sildenafil (Fig. 2). Both antagonists
themselves were not effective in ameliorating the control
response.
Hemodynamic effect of intravenous sildenafil
The baseline MAP and heart rate HR were 107 ± 1 mmHg
and 420 ± 3 beats/min, respectively. Furthermore, the
baseline MAP and HR in the several treatment groups did
not differ.
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RESULTS
Fig. 1. Temporal effect and dose response curves of intravenous saline (control) and sildenafil (n = 37) on mechanical threshold in rats following ligation of L5/6 spinal
nerves. Data are presented as paw withdrawal threshold (A) and %MPE (B). Intravenous sildenafil increased the withdrawal threshold in a dose-dependent manner.
Each line or bar represents mean ± SEM. BL, baseline. Compared with control, *p < 0.05, �p < 0.01. 
A B
The extent of change of MAP was not statistically signi-
ficant compared to baseline value over the 60 min-period
following the administration of intravenous sildenafil (1, 3,
10 mg/kg). However, 30 mg/kg of sildenafil significantly
augmented the extent of decrease of MAP at 5, 10 and 20
min (p < 0.05) (Fig. 3A). The extent of change of HR was
not statistically significant compared with baseline value
following intravenous sildenafil administration (Fig. 3B). 
Neuropathic pain occurs as a result of various conditions
that cause functional abnormalities or direct injury in the
nervous system or many diseases such as diabetic neuro-
pathy, postherpetic neuralgia, and trigeminal neuralgia.1-3
Central sensitization is the main contributor to the develop-
ment of neuropathic pain. The related symptoms are the
aberrant responses encountered in animal models and by
patients (i.e., hyperalgesia and allodynia).4,5 It is estimated
to afflict millions of people worldwide with neuropathic
pain. A previous study reported that a population prevalence
of neuropathic pain was about 8%.24 The management of
neuropathic patients is complex, and responses of patients
to treatments are inconsistently noted.25,26 Even with well-
established neuropathic medications, effectiveness is ina-
dequate and undesirable side effects are also troublesome.25,26
Thus, those phenomena have led to the development of
treatment modality that can be used in clinical practice. 
In the present study, intravenous sildenafil was found to
increase the paw withdrawal threshold after spinal nerve
ligation. Therefore, it is conceivable that the increased cGMP
level by inhibition of phosphodiesterase 5 may contribute to
the attenuation of the neuropathic pain at a systemic level.
Phosphodiesterase enzymes occur widely in biological
systems and are present in mammalian tissues.27 Phospho-
diesterase is an enzyme involved in the hydrolysis of cGMP,
and 11 subtypes of phosphodiesterase isoenzymes have
been identified on the basis of their functional characteris-
tics, such as substrate specificity, cellular distribution and
susceptibility to selective inhibitors.28 Among these isoen-
zymes, type 5 phosphodiesterase exerts the most signifi-
cant effect on the hydrolysis of cGMP.7 Of particular
interest, cGMP may play a pivotal role in the antinocicep-
tive mechanism. Several studies have indicated that
dibutyryl-cGMP, 8-bromo-cGMP and sildenafil produce
antinociception in various types of noxious stimulation.7,10-14
On the other hand, intravenous GABAA antagonist (bicu-
culline) and GABAB antagonist (saclofen) blocked the
antinociceptive effect of intravenous sildenafil in the
present study. These findings suggest that both GABAA
and GABAB receptors may contribute to the action of
sildenafil at a systemic level. 
In the hippocampus, GABA is the main inhibitory neuro-
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Fig. 2. The effects of intravenous bicuculline (16 mg/kg, n = 7) and saclofen (16
mg/kg, n = 8) on the antinociception by intravenous sildenafil (30 mg/kg) in spinal
nerve ligation-induced neuropathic pain. Bicuculline and saclofen were
administered 10 min before the delivery of sildenafil. Data are presented as
%MPE. Both bicuculline and saclofen attenuated the antinociception of
sildenafil. Neither bicuculline (n = 5) nor saclofen (n = 6) alone affected the
control response. Each bar represents mean ± SEM. Compared with sildenafil,
*p < 0.05, �p < 0.01.
Fig. 3. Temporal effect of intravenous saline and sildenafil (n = 25) on mean
arterial pressure (MAP, A) and heart rate (HR, B). Saline (control) and sildenafil
were administered at time 0. Percent change of MAP and HR from baseline is
plotted against time. Each line represents mean ± SEM. Compared with
baseline, *p < 0.05. 
A
B
transmitter, modulated by inhibitory GABA-releasing
interneurons.29,30 GABA is thought to be released from the
interneurons upon feed-forward inhibition by granule cells
or feedback inhibition by pyramidal cells.31 On the other
hand, cGMP appears to be involved in GABA release,
having effects of its own as well as a part of the nitric oxide-
cGMP pathway. It would therefore, appear that cGMP
analog increases the synaptic GABA release to labeled
paraventricular nucleus neurons.32,33 And increasing cGMP
level by superfusing slices with another phosphodiesterase
inhibitor (zaprinast) increases GABA release in the brain
stem, while a guanylyl cyclase inhibitor (ODQ) reduces
GABA release.15 Recently, it has been demonstrated that
potassium channels are downstream effectors of cGMP on
GABA release.33 Furthermore, the antinociception provoked
by sildenafil and dibutyryl-cGMP was reversed by potas-
sium channel blockers.10,34 These findings together suggest
that intravenous sildenafil increases the cGMP level by
inhibition of phosphodiesterase 5 and then induces the
release of GABA through a downstream mechanism,
involving potassium channels which act on GABA recep-
tors, in turn leading to an antinociceptive effect. 
As mentioned earlier, the activity of phosphodiesterase 5
was demonstrated in arterial and venous smooth muscle
cells.17 Moreover, phosphodiesterase 5 activity seemed to
be relevant to cGMP-linked vasodilatation.19 It is, therefore,
possible that phosphodiesterase 5 inhibitor may have signi-
ficant effect on hemodynamics. In this study, intravenous
sildenafil at the highest dosage used decreased MAP. On
the other hand, no significant change of HR response was
noted after intravenous sildenafil administration. Previous
studies showed modest effect of sildenafil on hemodyna-
mics. Oral sildenafil moderately reduced blood pressure in
normal humans.35 Furthermore, a significant decrease of
blood pressure was transiently observed with intravenous
sildenafil in healthy men, whereas HR was not affected.36
Particularly, the combination of sildenafil with nitric oxide
donors can potentiate the hypotensive effect by accumula-
tion of cGMP.37 Therefore, the concomitant use of sildenafil
with any drug which serves as a nitric oxide donor is absol-
utely contraindicated in clinics.38
Taken together, the current study provided an important
information about the signaling mechanisms through which
cGMP modulates the GABA receptors. These experiments
indicate that intravenous sildenafil attenuated mechanical
allodynia evoked by the ligation of spinal nerve. Such
antinociception may be mediated through GABAA and
GABAB receptors. This new information is expected to
deepen our understanding of the role of GABA receptors
for the action of intravenous sildenafil and indicates a
usefulness of sildenafil for neuropathic pain as a treatment
strategy. Furthermore, hemodynamic effect of intravenous
sildenafil should carefully be evaluated when given with
other antihypertensive drugs.
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